Publicaciones en las que colabora con José Luis Calleja Panero (19)

2024

  1. Porto-sinusoidal vascular liver disorder with portal hypertension: Natural history and long-term outcome

    Journal of Hepatology

  2. Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis

    Hepatology, Vol. 79, Núm. 3, pp. 624-635

  3. Predicting survival in patients with ‘non-high-risk’ acute variceal bleeding receiving β-blockers+ligation to prevent re-bleeding

    Journal of Hepatology, Vol. 80, Núm. 1, pp. 73-81

  4. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 2, pp. 201-211

  5. The Efficiency of Increased HCV Testing and Treatment Strategies in Spain to Achieve Elimination Goals

    PharmacoEconomics - Open, Vol. 8, Núm. 2, pp. 221-233

  6. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597

2023

  1. Alcohol-related liver disease phenotype impacts survival after an acute variceal bleeding episode

    Liver International, Vol. 43, Núm. 7, pp. 1548-1557

  2. Hepatic encephalopathy is not a contraindication to pre-emptive TIPS in high-risk patients with cirrhosis with variceal bleeding

    Gut, Vol. 72, Núm. 4, pp. 749-758

  3. Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 2, pp. 150-162

2022

  1. Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter study

    Alimentary Pharmacology and Therapeutics, Vol. 56, Núm. 1, pp. 131-143

2021

  1. Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis

    Journal of Hepatology, Vol. 75, Núm. 2, pp. 342-350

  2. Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

    Antiviral Research, Vol. 174

  2. Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))

    Journal of Hepatology

  3. Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS

    Journal of Hepatology, Vol. 73, Núm. 5, pp. 1082-1091

2019

  1. Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia, Vol. 42, Núm. 9, pp. 579-592

2015

  1. High efficacy and safety of triple therapy in hcv genotype 1 and moderate fibrosis: A multicenter study of clinical practice in Spain

    Annals of Hepatology, Vol. 14, Núm. 4, pp. 477-486

  2. Perfil clínico y seguimiento de los pacientes con hepatitis C crónica en hospitales españoles: Estudio disHCovery

    Revista Espanola de Quimioterapia, Vol. 28, Núm. 3, pp. 145-153

2012

  1. Portal hypertension: Recommendations for evaluation and treatment. Consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Center for Liver and Digestive Diseases (CIBERehd)

    Gastroenterologia y Hepatologia, Vol. 35, Núm. 6, pp. 421-450